From January 1, a new reimbursement list. What changes for patients?

A draft of the new list, which includes nine cancer therapies, fifteen non-oncology therapies, was presented at the Health Ministry on Monday. Eight therapies are dedicated to rare diseases. Seventeen therapies will be made available in drug programs while seven will be available in pharmacy reimbursement. One of the therapies has a high TLI status.

Among the new molecules are.

tislelizumab (three therapies, in different lines and combinations) for the treatment of patients with non-small cell lung cancer,

tislelizumab (three therapies, in different lines and combinations) for the treatment of patients with esophageal cancer, gastric adenocarcinoma or gastroesophageal junction,

erybulin in the treatment of adult patients with locally advanced or metastatic breast cancer,

Pentosan sodium polysulfate in the treatment of painful bladder syndrome,

iptacopan in the treatment of adult patients with nocturnal paroxysmal hemoglobinuria,

rADAMTS13 (an Adzynma drug funded under the Medical Fund) is the first enzyme replacement therapy for children and adults with congenital thrombotic thrombocytopenic purpura.

The Health Ministry has decided to include rysdyplam in tablet form in reimbursement, contrary to earlier signals, which the SMA patient community had already reported at the end of the week. As Deputy Health Minister Katarzyna Kacperczyk stressed at the press conference, this is a more convenient form to use than the syrup form of the drug, which has been covered for more than two years.

The pharmacy reimbursement will fund, among others, a three-component drug in the form of inhalation powder beclomethasone + formoterol + glycopyrronium for the treatment of chronic obstructive pulmonary disease and asthma, and a two-component product ramipril + indapamide for the treatment of hypertension in adult patients.

The Health Ministry also said that the new announcement extends reimbursement decisions made in the previous 2-3 years, which expire at the end of 2025. A total of 585 such decisions have been issued. They concern, among other things:

Nexviadyme (avalglucosidase alfa) - Pompe disease,

Kadcyla (trastuzumabum emtansinum) breast cancer,

Spinraza (nusinersen) spinal muscular atrophy (SMA),

Venclyxto (venetoclaxum) lymphocytic leukemia,

Jakavi (ruxolitinibum) - myeloproliferative neoplasms,

Padcev (enfortumabum vedotini) - urothelial cancer,

Givlaari (givosiranum) - acute hepatic porphyria.

The ministry has high hopes for savings from the inclusion in reimbursement of the first equivalents of ten original drugs. These include:

Midazolam - prolonged, acute seizures in adults

Glycopyrronium bromide - chronic obstructive pulmonary disease (COPD)

levodopa + carbidopa - Parkinson's disease and syndrome

denosumab - osteoporosis

epinephrine - anaphylactic reactions

Arsenic trioxide - acute promyelocytic leukemia

omalizumab - severe asthma, chronic spontaneous urticaria

eltrombopag - treatment of children and adults with primary immune thrombocytopenia

denosumab - prevention of bone complications in adult patients with advanced cancer

aflibercept - exudative age-related macular degeneration, diabetic macular edema.